Premium
The effects of an epithelial barrier protective cationic aerosol on allergen‐induced airway inflammation in asthma: a randomized, placebo‐controlled clinical trial
Author(s) -
Nair P.,
Denis S.,
Cancelliere L.,
Radford K.,
Efthimiadis A.,
Rosano M.,
Hanrahan J.
Publication year - 2014
Publication title -
clinical and experimental allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.462
H-Index - 154
eISSN - 1365-2222
pISSN - 0954-7894
DOI - 10.1111/cea.12383
Subject(s) - hypertonic saline , medicine , inhalation , allergen , immunology , placebo , airway , sputum , asthma , allergy , bronchoconstriction , methacholine , inflammation , eosinophil cationic protein , bronchitis , saline , eosinophil , anesthesia , lung , respiratory disease , pathology , tuberculosis , alternative medicine
Summary Inhaled cationic airway lining modulator (iCALM) is a cationic aerosol therapy comprised of 1.29% calcium chloride dissolved in 0.9% isotonic saline that enhances the biophysical barrier function of the airway lining fluid and primes the host defense response. It's ability to attenuate bronchitis caused by inhaled particles was investigated using an allergen‐inhalation model in a proof‐of‐concept study. In a randomized, double‐blind, placebo‐controlled cross‐over trial of 6 mild atopic steroid‐naïve asthmatic subjects, 3 doses of iCALM were well tolerated and they attenuated allergen‐induced increase in sputum eosinophils, and levels of IL‐5, MCP‐1 and eotaxin. This study provides an opportunity to investigate the role of enhancing epithelial barrier to decrease airway inflammation provoked by inhaled particles in a variety of airway diseases.